Pharma Innovation & Market Dynamics

Galecto’s acquisition of Damora Therapeutics, backed by a significant funding round, signals a promising advancement in targeted therapies for Myeloproliferative Neoplasms driven by the CALR mutation. The deal highlights a novel biotech launchpad model.

Facing financial headwinds, Biofrontera Inc. has sold its Xepi antibiotic cream to Pelthos Therapeutics, streamlining operations to prioritize its core photodynamic therapy business and pursue a viable path to profitability.

Pelthos Therapeutics expands its dermatology portfolio with the acquisition of Xepi, aiming to combat rising antibiotic resistance in impetigo treatment. A strategic move backed by robust funding.

Laborie Medical Technologies is expanding its obstetrics portfolio with the acquisition of the JADA System, a key device for postpartum hemorrhage control, while Organon focuses on core pharmaceutical strengths. The deal aims to improve patient outcomes and address a critical need in maternal health.

Harbour BioMed and Evinova are joining forces to leverage artificial intelligence in drug R&D, aiming to slash timelines and costs in the increasingly competitive biopharmaceutical landscape. A deep dive into the partnership and its implications.

A small medical device firm is making a bold move into the lucrative bone regeneration market, partnering with an Italian biomaterials innovator. Will this gamble pay off, or will established players shut them out?

MediciNova’s MN-166 (ibudilast) has received a key industry award, highlighting its potential in treating ALS. This comes amidst growing challenges in neurological disease research and limited effective treatments.

Innovative packaging protects delicate therapies, unlocking potential for personalized medicine. Cryoport’s solution is poised to capitalize on the booming regenerative medicine market.

ALZpath’s pTau217 antibody is earning accolades and gaining traction in the diagnostics market, promising earlier, more accessible detection of Alzheimer’s disease – but what are the broader implications?

A new skin biopsy test is showing promise for faster, more accurate diagnosis of debilitating neurodegenerative diseases, potentially opening doors to earlier intervention and improved patient care.

RenovoRx strengthens its pancreatic cancer program with a key advisory board appointment & promising data for its localized drug delivery system, potentially revolutionizing treatment.

RenovoRx strengthens its pancreatic cancer program with a key advisory board appointment & promising data for its localized drug delivery system, potentially revolutionizing treatment.

Small biotech Lisata Therapeutics wins major award for its innovative cancer drug delivery system, offering renewed optimism for hard-to-treat cancers like pancreatic cancer. A deep dive into the technology and future prospects.

A new approach to surgical site infection prevention, leveraging localized antibiotic delivery, has earned recognition and shows strong clinical results, potentially disrupting the $X billion market.

A breakthrough in genomic mapping offers a more complete picture of cancer-causing genetic changes, potentially revolutionizing diagnosis and treatment for leukemia patients.

The annual BioTech Breakthrough Awards highlight a surge in AI-driven innovation across the life sciences. We dissect the winners, trends, and investment signals shaping the future of biotech.

NewcelX Ltd. has appointed leading neuroimmunologist Prof. Tamir Ben-Hur to its Scientific Advisory Board, bolstering the biotech’s efforts to develop groundbreaking cell & small-molecule therapies for debilitating diseases like ALS and Type 1 Diabetes.

Dutch biotech firm SkylineDx is transforming cancer diagnosis with its innovative genomic tests, validated by research and earning industry recognition. Learn how they’re tailoring treatments for better patient outcomes.

New software from Golden Helix aims to democratize genomic data analysis, offering flexible pricing, cloud deployment & enhanced interpretation tools for labs of all sizes.

Amidst rising regulatory pressure and consumer demand for ethical sourcing, Oritain is expanding its scientific network. But are the promised acquisitions and new membership model fully materialized?